5 Key Takeaways

• 1

  Macular telangiectasia type 2 (MacTel) is a chronic, progressive retinal disease primarily affecting midlife patients.

• 2

  Early symptoms of MacTel include central vision loss and blunting of the foveal reflex, often leading to impaired daily activities.

• 3

  The FDA approved Encelto, the first therapy for nonproliferative MacTel, which slows photoreceptor loss through continuous CNTF production.

• 4

  Timely diagnosis and referral to retina specialists are crucial for effective management of MacTel and preventing significant vision loss.

• 5

  Patient counseling must set realistic expectations, as Encelto does not restore lost vision but slows disease progression.